VR Logo

Reata Pharmaceuticals Inc. Class A (RETA) download report


Healthcare | Biotechnology & Pharma Research

Reata Pharmaceuticals Inc. Class A (RETA) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases.

IPO Date: 26-May-2016

Chairman & CEO: Mr. J. Warren Huff

COO, CFO & Pres: Mr. Manmeet Singh Soni

Listing: NASDAQ: RETA

Country: United States

Headquarters: Plano, TX

Website: https://www.reatapharma.com

Key Facts

Market cap: $1,109.93 Mln

Revenue (TTM): $11.46 Mln

Earnings (TTM): $-303.77 Mln

Cash: $531.98 Mln

Total Debt: $141.59 Mln

Insider's Holding: 4.08%

Liquidity: Low

52 Week range: $20.24 - 144.70

Shares outstanding: 31,543,700

9 Years Aggregate:

  • CFO: $-1,197.69 Mln
  • EBITDA: $-879.14 Mln
  • Net Profit: $-1,005.62 Mln

Stock Performance

Time Period Reata Pharmaceuticals Inc. Class A (RETA) S&P BSE Sensex* S&P Small-Cap 600*
YTD15.43-8.62-18.78
1 month2.73-4.54-8.00
3 months-7.08-10.19-13.65
1 Year-78.491.43-17.19
3 Years-31.4110.146.10
5 Years-0.7711.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Reata Pharmaceuticals Inc. Class A (RETA) S&P Small-Cap 600 S&P BSE Sensex
2021-78.6725.2721.99
2020-39.539.5715.75
2019264.4020.8614.38
201897.36-9.705.87
201729.7311.7327.91